利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.033 秒)

    Methods of treatment of asthma and COPD
    11.
    发明授权
    Methods of treatment of asthma and COPD 有权

    公开(公告)号：US11197851B2

    公开(公告)日：2021-12-14

    申请号：US17177888

    申请日：2021-02-17

    申请人： Bridge Pharma, Inc.

    发明人： A. K. Gunnar Aberg ,  Vincent B. Ciofalo ,  Kresimir Pucaj

    IPC分类号： A61K31/4465 ,  A61K9/00 ,  A61P11/06 ,  A61K45/06

    摘要： Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

    Methods of treatment of non-histaminic pruritus
    13.
    发明授权
    Methods of treatment of non-histaminic pruritus 有权
    非组织型瘙痒症的治疗方法

    公开(公告)号：US09345697B2

    公开(公告)日：2016-05-24

    申请号：US14736626

    申请日：2015-06-11

    申请人： BRIDGE PHARMA, INC.

    发明人： A. K. Gunnar Aberg ,  Vincent B. Ciofalo

    IPC分类号： A01N43/40 ,  A61K31/445 ,  A61K31/4535 ,  A61K9/00

    CPC分类号： A61K31/4535 ,  A61K9/0053

    摘要： Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a psychological disorder, a mental disorder, a nerve disorder, or a systemic disorder.

    摘要翻译： 本文描述的是通过向有需要的哺乳动物施用治疗有效量的罗非洛芬或其药学上可接受的盐来治疗需要治疗非组胺性瘙痒症的哺乳动物的方法，从而减少对哺乳动物的划伤欲望。 非组胺能类型的瘙痒对选择性组胺H-1，H-2和H-4受体抑制剂的治疗具有抗性。 在某些方面，非组胺能性瘙痒与皮肤病，心理障碍，精神障碍，神经障碍或全身性疾病有关。

    Medicinal treatment of dermal diseases in dogs
    14.
    发明授权
    Medicinal treatment of dermal diseases in dogs 有权
    狗的皮肤疾病的药物治疗

    公开(公告)号：US08557846B1

    公开(公告)日：2013-10-15

    申请号：US13739090

    申请日：2013-01-11

    申请人： Bridge Pharma, Inc.

    发明人： A. K. Gunnar Aberg ,  Vincent B. Ciofalo

    IPC分类号： A61K31/4535

    CPC分类号： A61K31/4535 ,  A61K38/13

    摘要： The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of racemic norketotifen. Co-administrations with steroids or immunosuppressant drugs are described.

    摘要翻译： 本文公开的方法涉及通过施用治疗有效量的外消旋诺卡托芬来治疗狗中的真皮病症，例如特应性皮炎。 描述了与类固醇或免疫抑制剂药物的联合给药。

    Use Of RR/SR-Ractopamine
    15.
    发明申请
    Use Of RR/SR-Ractopamine 有权
    使用RR / SR-莱克多巴胺

    公开(公告)号：US20120015895A1

    公开(公告)日：2012-01-19

    申请号：US13227846

    申请日：2011-09-08

    申请人： A.K.Gunnar Aberg

    发明人： A.K.Gunnar Aberg

    IPC分类号： A61K31/7048 ,  A61P31/04 ,  A61P3/00 ,  A61K31/137 ,  A61P21/06

    CPC分类号： A61K31/137 ,  C07C211/27 ,  C07C211/36 ,  C07C215/60

    摘要： A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.

    摘要翻译： 公开了通过向动物施用治疗有效量的RR-莱克多巴胺和SR-莱克多巴胺的混合物来促进或改善动物的饲料效率和肌肉与脂肪比的方法。 提出制备RR / SR-莱克多巴胺的制备方法。

    Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
    16.
    发明申请
    Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion 审中-公开
    用化合物治疗弥漫性睑板腺分泌物的Xerophthalmia

    公开(公告)号：US20110294897A1

    公开(公告)日：2011-12-01

    申请号：US12956386

    申请日：2010-11-30

    申请人： A.K. Gunnar Aberg ,  Vincent B. Ciofalo

    发明人： A.K. Gunnar Aberg ,  Vincent B. Ciofalo

    IPC分类号： A61K31/137 ,  A61P27/04

    CPC分类号： A61K31/137 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/06 ,  A61K47/10

    摘要： Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof.

    摘要翻译： 通过使用肾上腺素能β受体激动剂，特别是沙丁胺醇，特别是光学纯的或基本上纯的R-对映体，治疗患有干眼症的患者的方法。 本文公开的实施方案包括通过向所述患者施用含有治疗有效量的肾上腺素能β受体激动剂的制剂来增加睑板腺脂质分泌并从而减少或消除干眼症状的方法。 特别地，本文公开的某些实施方案涉及含有R-沙丁胺醇作为活性β-受体刺激成分的组合物。 在某些实施方案中，将制剂施用于眼睛的眼表面和/或施用于有需要的患者的眼睑（眼睑的下侧和/或眼睑的顶部）。